/ Unknown status临床1/2期IIT Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.
A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine given with IL-12 for treatment-naïve patients after resection of glioblastoma.
100 项与 Hangzhou Medical Biotechnology Co., Ltd 相关的临床结果
0 项与 Hangzhou Medical Biotechnology Co., Ltd 相关的专利(医药)
100 项与 Hangzhou Medical Biotechnology Co., Ltd 相关的药物交易
100 项与 Hangzhou Medical Biotechnology Co., Ltd 相关的转化医学